Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 22507964)

1.

Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW, Penning TM.

Bioorg Med Chem Lett. 2012 May 15;22(10):3492-7. doi: 10.1016/j.bmcl.2012.03.085. Epub 2012 Mar 29.

2.

AKR1C3 as a target in castrate resistant prostate cancer.

Adeniji AO, Chen M, Penning TM.

J Steroid Biochem Mol Biol. 2013 Sep;137:136-49. doi: 10.1016/j.jsbmb.2013.05.012. Epub 2013 Jun 6. Review.

3.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
4.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

5.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
6.

Combinatorial androgen receptor targeted therapy for prostate cancer.

Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT.

Endocr Relat Cancer. 2006 Sep;13(3):653-66. Review.

7.

Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

Byrns MC, Jin Y, Penning TM.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16. Review.

8.

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.

Mellado B, Marin Aguilera M, Pereira MV.

Arch Esp Urol. 2013 Jun;66(5):453-62. Review.

PMID:
23793763
9.

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.

PMID:
21820046
10.

Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.

Cancer Biol Ther. 2006 Aug;5(8):901-6. Epub 2006 Aug 28. Review.

PMID:
16855379
11.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
12.

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.

Sadar MD.

World J Urol. 2012 Jun;30(3):311-8. doi: 10.1007/s00345-011-0745-5. Epub 2011 Aug 11. Review.

PMID:
21833557
13.

The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.

Chatterjee B.

Mol Cell Biochem. 2003 Nov;253(1-2):89-101. Review.

PMID:
14619959
14.

Antiandrogens in prostate cancer.

Reid P, Kantoff P, Oh W.

Invest New Drugs. 1999;17(3):271-84. Review.

PMID:
10665479
15.

Androgen biosynthesis in castration-resistant prostate cancer.

Penning TM.

Endocr Relat Cancer. 2014 Aug;21(4):T67-78. doi: 10.1530/ERC-14-0109. Epub 2014 May 14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk